Search results
Results from the WOW.Com Content Network
The National Board of Osteopathic Medical Examiners (NBOME), founded in 1934 as the National Osteopathic Board of Examiners for Osteopathic Physicians and Surgeons, Inc., [1] [2] is a United States examination board which sets state recognized examinations for osteopathic medical students and began administering exams in February 1935.
The National Board of Medical Examiners (NBME), founded in 1915, is a United States non-profit which develops and manages assessments of student physicians. Known for its role in developing the United States Medical Licensing Examination (USMLE) in partnership with the Federation of State Medical Boards (FSMB), USMLE examinations for medical students and residents are used by medical licensing ...
The 25-NB (25x-NBx) series, or NBOMe series, also known as the N-benzylphenethylamines, is a family of serotonergic psychedelics. [1] [2] They are substituted phenethylamines and were derived from the 2C family. [2] The most commonly encountered NBOMe drugs are 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe. [3]
Like other 2C-X-NBOMe molecules, 25I-NBOMe is a derivative of the 2C family of phenethylamines described by chemist Alexander Shulgin in his book PiHKAL. [17] [15] Specifically, 25I-NBOMe is an N-benzyl derivative of the phenethylamine molecule 2C-I, formed by adding a 2-methoxybenzyl (BnOMe) onto the nitrogen (N) of the phenethylamine backbone ...
25B-NBOMe (NBOMe-2C-B, Cimbi-36, Nova, BOM 2-CB) is a derivative of the phenethylamine psychedelic 2C-B, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent full agonist for the 5HT 2A receptor .
25TFM-NBOMe (also known as NBOMe-2C-TFM, 2C-TFM-NBOMe, and Cimbi-138) is a derivative of the phenethylamine hallucinogen 2C-TFM, discovered in 2004 by Ralf Heim at the Free University of Berlin. [1]
25D-NBOMe (or NBOMe-2C-D) is a derivative of the phenethylamine derived hallucinogen 2C-D. It acts in a similar manner to related compounds such as 25I-NBOMe , which is a potent agonist at the 5-HT 2A receptor .
25I-NB3OMe is not explicitly listed as a controlled substance in the United States, but is a positional isomer of 25I-NBOMe [3] and thus may be considered a Schedule I drug under the Federal Analogue Act, meaning that it would be subject to the same penalties for possession, distribution, and manufacture as 25I-NBOMe.